Seelos therapeutics to participate in the guggenheim 4th annual immunology and neurology day

New york , nov. 7, 2022 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the guggenheim 4th annual immunology and neurology day, november 14 th and 15th. raj mehra, ph.d.
SEEL Ratings Summary
SEEL Quant Ranking